SB202190 (FHPI)

Name: SB202190 (FHPI)
Brand: Selleck Chemicals
SKU: S1077
Rating: 5 (107 reviews)

For research use only.

Catalog No.S1077

107 publications

CAS No. 152121-30-7

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

Selleck's SB202190 (FHPI) has been cited by 107 publications

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

J Mol Med (Berl), 2021, 10.1007/s00109-021-02047-5

PubMed: 33611659 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )
J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Theranostics, 2019, 9(17):5065-5084

PubMed: 31410202 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )
J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )

J Physiol Biochem, 2019, 75(4):475-487

PubMed: 31399951 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

J Virol, 2018, 92(4)e01463-17

PubMed: 29167338 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Sci Rep, 2017, 7(1):7442

PubMed: 28785085 ( click the link to review the publication )
Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

J Dent Res, 2016, 95(7):769-75

PubMed: 26961489 ( click the link to review the publication )

Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Sci Rep, 2016, 6:30904

PubMed: 27485764 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )
Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	NXnRcHhiTnWwY4Tpc44hSXO\|YYm=	NEPE[YQzPSEQvF2=	MWqzNEBucW5?	MlP6SG1UV8Li	MmXaZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG=	NInUcZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKyN\|I2OSd-Mk[yNlMzPTF:L3G+
MDA-MB-231	M1PRPGZ2dmO2aX;uJGF{e2G7	MkHKNkDPxE1?	NWPEN3ZrOjRiaB?=		MUns[ZN{\W6nczDDR2wzKGmwZIXjeIlwdiCkeTDUUmbPuQ>?	NVvDTY1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFA5PDhpPkK2NVAxQDR6PD;hQi=>
rBMSCs	M1;rXWZ2dmO2aX;uJGF{e2G7	MojzNVAh\|ryP	NGr6UFgzNjViaB?=		MYXk[ZBz\XO\|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB\|OB?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3M{K2Okc,OjZyNUOyOlY9N2F-
MG63	NETibWFHfW6ldHnvckBCe3OjeR?=	MVixNE8zOC9\|MDFOwG0>	M4O0clI1KGh?		NWP4OJR[e2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgeIhmKGyndnXsJI9nKHCqb4PwbI9zgWyjdHXkJJA{QCCrbnT1Z4VlKGK7IFPkR4wzKGmwIHGgZ49v[2WwdILheIlwdiBvZHXw[Y5l\W62IH3hco5meg>?	NVewVGw1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PVg{OTJpPkK1PVk5OzF{PD;hQi=>
MG63	MYXBdI9xfG:\|aYOgRZN{[Xl?	Mn:xNVAwOjBxM{Cg{txO	NIrrNJIzPCCq		MXHzbYdvcW[rY3HueIx6KGSnY4LlZZNm\CC2aHWgZZBweHSxc3nzJJJifGVib3[gUWc3OyCrbnT1Z4VlKGK7IFPkR4wz	NULE[nVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PVg{OTJpPkK1PVk5OzF{PD;hQi=>
HTSMCs	NXjQXlY1TnWwY4Tpc44hSXO\|YYm=	MXqwMlEwOS9zMDFOwG0>	Ml;MNUBp		MYfpcohq[mm2ZXSgR29TVS1{LXnu[JVk\WRiSF:tNUBxem:2ZXnuJIxmfmWuczDhcoQhdVKQQTDlfJBz\XO\|aX;u	M33WVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUKxOFY1Lz5{NUmyNVQ3PDxxYU6=
MIA PaCa-2	NUH1bHFlTnWwY4Tpc44hSXO\|YYm=	MoPwNlDDqM7:TR?=	NHq1WFczPCCq		NEHWbHpz\WS3Y3XkJIxi[3SjdHWgZYNkfW23bHH0bY9vKGmwIHPvcYJqdmG2aX;uJJdqfGhiYn;0bEAzNUSJIHHu[EBFNWGubH;z[eKh	NW\HTWo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
MIA PaCa-2	MUXGeY5kfGmxbjDBd5NigQ>?	MmjXNlDDqM7:TR?=	NVO3cIhSOjRiaB?=		MmLzdoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y\|rFicILveIVqdiCjY3P1cZVt[XSrb36=	M3XpR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
BxPC-3	M1TWZ2Z2dmO2aX;uJGF{e2G7	NHG0b\|EzOMLizszN	M4q0OFI1KGh?		M1jaUZJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
AsPC-1	M3nyfWZ2dmO2aX;uJGF{e2G7	M{O1XlIxyqEQvF2=	MUSyOEBp		NVyybJQ2emW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	NYXVXJZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
MIA PaCa-2	NF7PSZhHfW6ldHnvckBCe3OjeR?=	Ml\aNlDDqM7:TR?=	Mk\xNlQhcA>?		M3LUToVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCge4hmdiClb33ibY5m\CC5aYToJIdtfWOxc3WgZY5idG:pcx?=	M2XPdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
MIA PaCa-2	NVHXXm16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoC0NlDDqM7:TR?=	NWTKb2pCOiCq		M33q[5NmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	Mor0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
BxPC-3	M3r2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NImyPG8zOMLizszN	MXWyJIg>		MV\z[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
AsPC-1	NG\sZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPiNlDDqM7:TR?=	NE\XTmEzKGh?		NI\WRoN{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MlrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
HEY	MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPKNlDDqM7:TR?=	NHvQ[VYzKGh?		M{HYcpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	M{i5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
OVCAR-3	NFfsT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOyNOKh\|ryP	MUKyJIg>		M1\B[pNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NFfuO4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
SK-OV-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofzNlDDqM7:TR?=	M3fBVFIhcA>?		Mn7ad4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	NICyd2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
MH7A	Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYD4S2Y4OjRiaB?=		NFW2Todz\WmwZn;yZ4V{KHSqZTDpcohq[mm2b4L5JIVn\mWldIOgc4YhYEGQ	M3vCZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[yPVY3Lz5{NUi2Nlk3PjxxYU6=
MH7A	NV65eHBtSXCxcITvd4l{KEG\|c3H5	MnfyNlUh\|ryP	M3;6TVI1KGh?		MX3y[ZZmenOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpcoR2[2WmIHL5JHhCViCjbnSgZ4F2e2WmIHHwc5B1d3OrczDv[kBk\WyuczD2bYEh[WO2aY\heIlwdiCxZjDKUms>	M4jEbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[yPVY3Lz5{NUi2Nlk3PjxxYU6=
SCC25	NW[5cmxwTnWwY4Tpc44hSXO\|YYm=	NX3xOXZ5OjBizszN	MkPRNlQhcA>?		NH7NT5JqdmO{ZXHz[ZMh[XW2b4DoZYd6KGyndnXs	M{nSN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAxLz5{NUizOFQxODxxYU6=
HaCaT	MkfmSpVv[3Srb36gRZN{[Xl?	NEGyVFQ2KML3TR?=	NH60WVgzPCCq		MY\pcohq[mm2czDJSm4u\|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	Ml;TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{SzOVMoRjJ3OEO0N\|U{RC:jPh?=
HaCaT	MkDnSpVv[3Srb36gRZN{[Xl?	Ml7JOUDDvU1?	M4\sRVI1KGh?		M4L3OolvcGmkaYTzJGlHVi4QsT3pcoR2[2WmIFPDUFIzKHC{b3T1Z5Rqd25ibHX2[Yx{	Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{SzOVMoRjJ3OEO0N\|U{RC:jPh?=
HPAEpiCs	MUPGeY5kfGmxbjDBd5NigQ>?	MXWxM\|MwOTBizszN	NEHPcoMyKGh?		NYXBSWM3emWmdXPld{BUOVBvaX7keYNm\CCLQ1HNMVEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd\|NEmwNEc,OjV5M{S5NFA9N2F-
HPAEpiCs	NHTNSoRHfW6ldHnvckBCe3OjeR?=	MWCxM\|MwOTBizszN	NHjBcZIyKGh?		Mo\YbY5pcWKrdIOgV\|FRNXO2aX31cIF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbjCgxsA>	MmCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{S5NFAoRjJ3N{O0PVAxRC:jPh?=
HPAEpiCs	Moq4SpVv[3Srb36gRZN{[Xl?	MmLNNU8{NzFyIN88US=>	NUPUZmxNOSCq		NYOzNYlNcW6qaXLpeJMhWzGSIITpcYUu\GWyZX7k[Y51dHlic4TpcZVt[XSnZDDjMWp2diCyaH;zdIhwenmuYYTpc44>	M3voU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{O0PVAxLz5{NUezOFkxODxxYU6=
K562	M4TCNWZ2dmO2aX;uJGF{e2G7	NH7CU2oyOMLizszN	NH3KXY0yyqCq	NGXpWopFVVOR	NIXRS2FqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u	M3Pre\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nki0NFQ{Lz5{NU[4OFA1OzxxYU6=
PANC-1	MVPGeY5kfGmxbjDBd5NigQ>?	MWSxNEDPxE1?	M1W3SVEhcA>?		NXjufG9Y\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC=	NFTuZ2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzOid-MkW2N\|IzOjJ:L3G+
BxPC-3	MUHGeY5kfGmxbjDBd5NigQ>?	M1izUFExKM7:TR?=	NVvXS3B[OSCq		NVXqd\|Bt\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyNkc,OjV4M{KyNlI9N2F-
K562	NXnmOI9HTnWwY4Tpc44hSXO\|YYm=	NVPubYZrOC5{NT2xJO69VQ>?	MkXjNlQhcA>?		Mn24d5VxeHKnc4Pld{Bz\XO4ZYLheJJwdC2rbnT1Z4VlKEh{QWigdIhwe3Cqb4L5cIF1cW:w	M1rJblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkG5N\|kzLz5{NU[xPVM6OjxxYU6=
THP-1	MULGeY5kfGmxbjDBd5NigQ>?	NUjXNJVUPSEEtV2=	M{DTd\|IhcA>?		NXLNdlZPe2mpbnnmbYNidnSueTDheJRmdnWjdHXzJJNm[3KndHnvckBw\iCLTD2x{tEhcW6mdXPl[EBjgSB{N1;IR4hwdCCybIXzJGZUVC1zwrC=	M2PSV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm4OlYyLz5{NUW5PFY3OTxxYU6=
WB	Mn\wSpVv[3Srb36gRZN{[Xl?	NU\LVIh6OjEkgJpOwG3DqA>?	NXO2e3FKOzEkgJntbY4>		NH7pdZVl\WO{ZXHz[ZMhfGinIFzQV{0hd3JiTGTBMYlv\HWlZXSgTWwuPiCjbnSgWG5HNc7zwrDwdo9lfWO2aX;u	Mm\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{C2PFIoRjJ3NUOwOlgzRC:jPh?=
RAW 264.7	M{LCWGZ2dmO2aX;uJGF{e2G7	MWOxNOKh\|ryP	MYSzNQKBkW2rbh?=		MWDpcoR2[2W\|IHPoZZJi[3SncnnzeIlkKH[jY4XvcIF1cW:wIH;mJG9Ee8Li	NVvRW2VrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlE{QTlpPkK1OFYyOzl7PD;hQi=>
RAW 264.7	NGTJNlBHfW6ldHnvckBCe3OjeR?=	MUixNOKh\|ryP	NWC2NXRiOzEkgJntbY4>		NF;CXJhifHSnboXheIV{KHSqZTDl[oZm[3S\|IH;mJG9RTyCxbjDvd5Rmd2OuYYP0JJJmfHKjY4Tpc44>	NUXuNJloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlE{QTlpPkK1OFYyOzl7PD;hQi=>
HaCaT	M2izV2Z2dmO2aX;uJGF{e2G7	M{PqVVQxyqEQvF2=	MnrxN{0zPCCq	NGWycHVFVVOR	NUXhSXlKemWmdXPld{B1cGViYXPjeY12dGG2aX;uJI9nKFqRLUG=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|NUS4OUc,OjV2M{W0PFU9N2F-
H9c2	NIS1XFZHfW6ldHnvckBCe3OjeR?=	MkD3OVDDqM7:TdMg	MmfXNVIhcA>?		Mle3doVlfWOnczDMSGghemWuZXHz[UBidmRiTV3QJIxwe3N?	NIjnOWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0OVgyQCd-MkWyOFU5OTh:L3G+
HSCs	NIi5ZmVCeG:ydH;zbZMhSXO\|YYm=	NF\2elkzPSEQvF2=	MYqyOOKhcA>?		M3PPfZNq\26rZnnjZY51dHliYYT0[Y52[XSnczDUS{1qdmS3Y3XkJIFkfGm4YYTl[EBJW0O\|IHHwc5B1d3Orcx?=	NVziXXNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE6PTBpPkK0PVYyQTVyPD;hQi=>
THP-1	NHTEOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlyzO\|IhcA>?	NEDKZ3FFVVOR	NGHmeFdKSzVyPUSuO:69VQ>?	NISzRWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixOVA5Pyd-MkS4NVUxQDd:L3G+
MDDCs	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVW3NkBp	M3\SUGROW09?	NYHE[WxpUUN3MEKuO:69VQ>?	MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUWwPFcoRjJ2OEG1NFg4RC:jPh?=
MDDCs	NGOxd3ZHfW6ldHnvckBCe3OjeR?=	MkixNE0yPSEQvF2=	MknUOFghcA>?	NFfGbWdFVVOR	Mknmd5VxeHKnc4Pld{BKTk5vzsGgZY5lKEmSLUGwJJBzd2S3Y4Tpc47DqA>?	NIjLWnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixOVA5Pyd-MkS4NVUxQDd:L3G+
MDDCs	M{HmWGZ2dmO2aX;uJGF{e2G7	M2HLN\|AuOTVizszN	MVK0PEBp	NHzZe3lFVVOR	NEnOclZqdmirYnn0d{BOUVBvMXGsJG1KWC1zYjDhcoQhWkGQVFXTJJBzd2S3Y4Tpc44>	NYD5fYU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	M1rJemZ2dmO2aX;uJGF{e2G7	MnPnNVAh\|ryP	NFXSTmI{NjViaB?=	NFnKcmNFVVOR	NF7zbmFjdG:la4OgSWJQXiCJUDygZpV1KG6xdDDWV3YhTyCvZXTpZZRm\CCnboTyfUBqdnSxIHj1cYFvKE2GRFPz	NYXlUld[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
macrophages	M4rS[2Z2dmO2aX;uJGF{e2G7	NGOye\|Uy6oDLzszN	MV60MlXjiImq		NGfUfnlkd22ybHX0[Yx6KGmwaHnibZR{KE2WLVnJTU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiTl[t{tpD	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyOE[zN{c,OjR6MEi2N\|M9N2F-
PDL	NIrR[oRHfW6ldHnvckBCe3OjeR?=	NFqyUFAzOMLizszNxsA>	NXvXU4w3OzBibXnu	M2f6T2ROW09?	NHv5WG5{cWewaX\pZ4FvfGy7IHnubIljcXS\|IITo[UB1\W6\|aXzlJIZwemOnLX3l[IlifGWmIFLNVE0zKGW6cILld5Nqd25?	NUHnU4ljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlExQDFpPkK0OVYyODhzPD;hQi=>
AGS	MnG3SpVv[3Srb36gRZN{[Xl?	Ml\MOUDPxE1?	NHzWc2c{OCCvaX6=		MVfzeZBxemW\|c3XzxsAyNWmwZIXj[YQh[2G\|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV2N{i3PEc,OjR3NEe4O\|g9N2F-
H520	MmL6SpVv[3Srb36gRZN{[Xl?	MYqxNOKhyrWP	MkSzNUBp	NH36fXBFVVOR	NGDvdFll\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz	MnvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3M{C0O\|UoRjJ2NUOwOFc2RC:jPh?=
H1703	MmLNSpVv[3Srb36gRZN{[Xl?	NHjndG8yOMLiwsXN	NUHSOXR[OSCq	M4W4eGROW09?	M1mzU4Rm[3KnYYPld{B1cGVicHXt[ZRz\XinZD3pcoR2[2WmIF3TTFIhdVKQQTDhcoQheHKxdHXpckBt\X[nbIO=	M3T0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
H520	NXXZPWQ3TnWwY4Tpc44hSXO\|YYm=	NVTub4o3OTEEoNM1US=>	NF\TUmoyOiCq	MlTNSG1UVw>?	NXjwO3Y5cW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	NF3hPYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H1703	M131fGZ2dmO2aX;uJGF{e2G7	M1r6SVExyqEEtV2=	NFPUVZoyOiCq	NHnHWJRFVVOR	MXjpcohq[mm2czDw[Y1mfHKneHXkMYVtcWOrdHXkJG1UUDJicILveIVqdiC\|dHHibYxqfHl?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
H520	NInOT4JHfW6ldHnvckBCe3OjeR?=	NG\UO2kyOMLiwsXN	M4\ZVlYhcA>?	MV7EUXNQ	MnXCd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	NVG4TJNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|A1PzVpPkK0OVMxPDd3PD;hQi=>
H1703	MknZSpVv[3Srb36gRZN{[Xl?	NFS1eFAyOMLiwsXN	MmCwOkBp	M2e0PGROW09?	MWjzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy\|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
MC3T3-E1	MmKzSpVv[3Srb36gRZN{[Xl?	MViwMlMwOy9\|MDFOwG0>	M4PMZVEhcA>?		MkO5ZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC=	M37rZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUCyOlk3Lz5{NEWwNlY6PjxxYU6=
MC3T3-E1	NYP6PYJTTnWwY4Tpc44hSXO\|YYm=	MkDCN\|Ah\|ryP	MoHZNUBp		NYDvUYJz[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	NGnUTYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwNlY6Pid-MkS1NFI3QTZ:L3G+
HUVECs	NWXyPIpRTnWwY4Tpc44hSXO\|YYm=	MVuxNOKhyrWP	MWexJIg>		NHzzNGdqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDDXGNNOSCycn;keYN1cW:w	MkH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEe5OlQoRjJ2NEi3PVY1RC:jPh?=
AGS	NVnQdFNiTnWwY4Tpc44hSXO\|YYm=	MWSxNOKhyrWP	Mk\JN\|DDqG2rbh?=		NYHUPFE2cW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i=	MmfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
MKN-45	M2fxdGZ2dmO2aX;uJGF{e2G7	MUGxNOKhyrWP	MnXIN\|DDqG2rbh?=		MnfpbY5pcWKrdIOgTWwuOc7{LXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOzh?	NI\3fo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3PVY5OSd-MkS0O\|k3QDF:L3G+
AGS	Mk\MSpVv[3Srb36gRZN{[Xl?	NYn3TGdlOTEEoNM1US=>	NXfBV2VIOzEEoH3pci=>		NVvXTY1V[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
MKN-45	NELsSo1HfW6ldHnvckBCe3OjeR?=	MXWxNOKhyrWP	NHv4NmI{OMLibXnu		NIq1OIRifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
AGS	MYXGeY5kfGmxbjDBd5NigQ>?	NEnoTXcyOMLiwsXN	MXGzNOKhdWmw		MWrzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>?	Mkn3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
MKN-45	M1L0cmZ2dmO2aX;uJGF{e2G7	MlnYNVDDqML3TR?=	MknJN\|DDqG2rbh?=		M{OzZZNq\26rZnnjZY51dHliZHXjdoVie2W\|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w	NH7B[ms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3PVY5OSd-MkS0O\|k3QDF:L3G+
DCs	NEjnbZZHfW6ldHnvckBCe3OjeR?=	NVLSR3NwOjEEoN88US=>	MknCNeKhcA>?		NXPBO\|Ri\GWlcnXhd4V{KEmOLUGyJJBzd2S3Y4Tpc44>	Mnu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{S2N\|YoRjJ2NEO0OlM3RC:jPh?=
HUVEC	NGH2dYZHfW6ldHnvckBCe3OjeR?=	MmHzNlAh\|ryvwrC=	M4jZV\|UhcA>?	MkntSG1UVw>?	M{D0bJJm\HWlZYOgZ5l1d2urbnWg[ZhxemW\|c3nvckBt\X[nbIOgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK=	MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzOEmwOlIoRjJ2MUi5NFYzRC:jPh?=
A 549	NFvUSm1HfW6ldHnvckBCe3OjeR?=	M2LNZVUxKM7:TR?=	NWTPOopLOSCq		M2\0TIRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiSVytPOKh	M17u[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe5Olg5Lz5{NEG3PVY5QDxxYU6=
H520	MVjGeY5kfGmxbjDBd5NigQ>?	MVS1M\|ExKM7:TR?=	M1fSfVEhcA>?	M1nkV2ROW09?	MWnk[YNz\WG\|ZYOgUXNJOiCycn;0[YlvKGG\|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?=	NWK4b456RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|g6ODNpPkK0NVM5QTB\|PD;hQi=>
H1703	M1TJfWZ2dmO2aX;uJGF{e2G7	NFKyZoM2NzFyIN88US=>	M4XXR\|EhcA>?	NXTiOopoTE2VTx?=	MnHD[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG\|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy=	NHTVblY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzPFkxOyd-MkSxN\|g6ODN:L3G+
H520	M4HpR2Z2dmO2aX;uJGF{e2G7	MVixNOKhyrWP	MoTSNVIhcA>?	MnvGSG1UVw>?	M4XKfoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	MlnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{i5NFMoRjJ2MUO4PVA{RC:jPh?=
H1703	M2rLXmZ2dmO2aX;uJGF{e2G7	NHjYSGQyOMLiwsXN	Mn;vNVIhcA>?	M{[1dGROW09?	M{\iRoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	NGPZcYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzPFkxOyd-MkSxN\|g6ODN:L3G+
MCF-7	M33SfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUixNOKh\|ryP	MmruNlTDqGh?		M4D2fYlvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg>	NEfxN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyPFg2Oyd-MkSxNlg5PTN:L3G+
HPAEpiCs	NV7RSIF7TnWwY4Tpc44hSXO\|YYm=	Mo[zNE4yNzFxMUCg{txO	NHm1fHMyKGh?		M3;WcYlvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPQUGEzyqCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25?	MkC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmxOVgoRjJ2ME[5NVU5RC:jPh?=
podocytes	MnKySpVv[3Srb36gRZN{[Xl?	M{LRflExyqEQvF2=	NFrHb4kyKGh?		M4nFVIlvcGmkaYTzJHRITs7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6TVHQT{BidmRiRYLrNU8zyqB?	NWT1VIU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwN\|YzOTJpPkK0NFM3OjF{PD;hQi=>
MCF-7	M1fTU2Z2dmO2aX;uJGF{e2G7	MojONVDDqM7:TR?=	M{DkT\|EhcA>?	MmfmSG1UVw>?	M3XH[ZJm\HWlZYOgeIhmKFeDLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQheDN6IF3BVGs>	M1\VWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG5NFkxLz5{NECxPVA6ODxxYU6=
MCF-7	MnfHSpVv[3Srb36gRZN{[Xl?	M3HHV\|ExyqEQvF2=	MWCyOEBp	NYrpd2xITE2VTx?=	MmC1bY5kemWjc3XzJJRp\SCZQT3pcoR2[2WmIHHwc5B1d3Orcx?=	NUezS5VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVkxQTBpPkK0NFE6ODlyPD;hQi=>
HAPI	Mn7kSpVv[3Srb36gRZN{[Xl?	NWTxSm94OTBxMkCvOFDDqM7:TR?=	M{Tt[FEhcA>?		NFPWRoVqdmirYnn0d{BVS0SGLXnu[JVk\WRicEO4M2pPUyCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	NX3PfHFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlkyOjBpPkKzPVY6OTJyPD;hQi=>
HAPI	NE\rb2RHfW6ldHnvckBCe3OjeR?=	NYLHcIhjOjEEoN88UeKh	NYX5WHRSOSCq	NIW1PYNFVVOR	M{LzOIF1fGWwdXH0[ZMhXEOGRD3pcoR2[2WmIHHjeIl3[XSrb36gc4YhcU6RUzDhcoQheHKxZIXjeIlwdg>?	NG\USFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2PVEzOCd-MkO5OlkyOjB:L3G+
HepG2	MWfGeY5kfGmxbjDBd5NigQ>?	MmDoN\|UxKG6P	NVzFN5BTOjRiaB?=		MofabY5pcWKrdIOgeIhmKGSnZ4XlcIlvNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDwN\|hOSVCN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|M{G5PEc,OjN7M{OxPVg9N2F-
AGS	NGP5SIVHfW6ldHnvckBCe3OjeR?=	MkjnNVDDqM7:TR?=	MWqzNEBucW5?		MY\pcohq[mm2czDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiaX7obYJqfGmxbjDv[kBGWkt?	MnTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC5PVQoRjJ\|OEWwPVk1RC:jPh?=
HepG2	NHXEUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWSwMVUxKM7:TR?=	MVK0PEBp		MYfpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NYTRU4wyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NFc2ODhpPkKzPFA4PTB6PD;hQi=>
BEL7404	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDmNE02OCEQvF2=	MVi0PEBp		NG\rOJZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M4PUR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEC3OVA5Lz5{M{iwO\|UxQDxxYU6=
HL7702	NYDLdoJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHG1XnIxNTVyIN88US=>	MXm0PEBp		NWLn[Gt{cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M1vEZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEC3OVA5Lz5{M{iwO\|UxQDxxYU6=
HepG2	NYKyWZZTTnWwY4Tpc44hSXO\|YYm=	MXiwMVUxKM7:TR?=	NHe4WpIzPCCq		M4XPT4lvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26\|dILlZY0heHKxdHXpcpMhVUGSS1HQT\|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyN{WwPEc,OjN6MEe1NFg9N2F-
BEAS-2B	NVTnTFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV2xNEDPxE1?	MXOzNEBucW5?		MYPy[ZZmenOnczD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKQ1m=	NG\rRZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4OFA{PCd-MkO3PFQxOzR:L3G+
BEAS-2B	NYDmSm9iS3m2b4TvfIl1gSCDc4PhfS=>	NGXSeIIyOCEQvF2=	NF;YWWk{OCCvaX6=		M4DhRolvcGmkaYTl[EB1cGViaX7jdoVie2ViaX6gUGRJKGGwZDDJUE05KGW6cILld5Nqd25?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd6NECzOEc,OjN5OESwN\|Q9N2F-
BEAS-2B	NUC3VVVKTnWwY4Tpc44hSXO\|YYm=	MVuxNEDPxE1?	NFK4S3U{OCCvaX6=		NYjQbY1V\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ4F{eGG\|ZT2zMEBD[WRiYX7kJIZiew>?	Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OESwN\|QoRjJ\|N{i0NFM1RC:jPh?=
H9c2	MYjGeY5kfGmxbjDBd5NigQ>?	NILXOIkxNjBzL{CuNU8yKM7:TR?=	NELRbFIyKGh?		M2T2NYF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjygcXJPSSCuZY\lcJMtKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd5NEK1Nkc,OjN5N{SyOVI9N2F-
H9c2	NGLmU4ZHfW6ldHnvckBCe3OjeR?=	MVixJO69VQ>?	NVnRXYdrOSCq		M{XFfZJm\HWlZYOgWG5HNc7zIHTpdoVkfGy7IIP0bY12dGG2ZXSgdFM5KE2DUFugdIhwe3Cqb4L5cIF1cW:w	M1;6clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{e0NlUzLz5{M{e3OFI2OjxxYU6=
U937	MmjDSpVv[3Srb36gRZN{[Xl?	NWLyZm15OTEEoN88UeKh	MkfyNUBp		MULhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6\|Y4LpdJRqd26jbDDs[ZZmdHN?	NVPYe2hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFc{QDdpPkKzO\|A4Ozh5PD;hQi=>
U937	MofYSpVv[3Srb36gRZN{[Xl?	MVGxNOKh\|ryPwrC=	MW[xJIg>		MnXkZYJzd2ejdHXzJINi\m[naX7lMYlv\HWlZXSgUWtRNTFiZH;3ck1z\We3bHH0bY9vKGGwZDDQVFJC[87zIIXwMZJm\3WuYYTpc44>	M4DkWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3N\|g4Lz5{M{ewO\|M5PzxxYU6=
U937	MXHGeY5kfGmxbjDBd5NigQ>?	MofWNVDDqM7:TdMg	NV7wWWU{OSCq		M4fUTJN2eHC{ZYPz[ZMh[y2MdX6gZY5lKEOURVKgdIhwe3Cqb4L5cIF1cW:wIHnuJINi\m[naX7lMZRz\WG2ZXSgZ4VtdHQEoB?=	NXrpdYVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFc{QDdpPkKzO\|A4Ozh5PD;hQi=>
A549	M2LjRWZ2dmO2aX;uJGF{e2G7	NFfVfY8xNjNxMz:zNEDPxE1?	Mm\vNUBp		M1nVRpNq\26rZnnjZY51dHliYYT0[Y52[XSnczDBWHDPu1NvbXXkbYF1\WRiQ1;YMVIheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2edMg	NED2c5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
A549	NXrXVYpnTnWwY4Tpc44hSXO\|YYm=	NXP1PYUyOTEEoN88UeKh	MnnONE0{OCCvaX6=		NFiyVmxqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDwOFIweDR2IF3BVGsh[W6mIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>?	NI\ldpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
A549	MWjGeY5kfGmxbjDBd5NigQ>?	MXyxNOKh\|ryPwrC=	NIXseZkyKGh?		M3\rc4lvcGmkaYTzJGFVWM7\|UzDpcoR2[2WmIF7GMe67SiCyNkWgd5VjfW6rdDDwbI9{eGixconsZZRqd25iYX7kJG5HNc78QjDwdo9ud3SncjDhZ5Rqfmm2eR?=	M1PYdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkiwOlc1Lz5{M{[4NFY4PDxxYU6=
A549	NFfidJJHfW6ldHnvckBCe3OjeR?=	MVSxNOKh\|ryPwrC=	NHz0cWUyKGh?		M{nkbJJm\HWlZYOgRXRR\|rOVLYP0bY12dGG2ZXSgZ3BNSTJicHjvd5Bpd3K7bHH0bY9vyqB?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6ME[3OEc,OjN4OEC2O\|Q9N2F-
A549	M37NTWZ2dmO2aX;uJGF{e2G7	NXnOcZgyOTEEoN88UeKh	MlfaNUBp		MnTvdoVlfWOnczDBWHDPu1NvZX7oZY5k\WRiZX76fY1ifGmlIHHjeIl3cXS7IH;mJINRVEF{wrC=	NYjqc4dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
PC12	NWfO[pRKTnWwY4Tpc44hSXO\|YYm=	NXfGUoN6OTBxMkCvOFAh\|ryP	MoHLNeKhcA>?		NFPNWpFqdmirYnn0d{BLVktiYX7kJJA{QA>?	NFS1coc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4OFM2Pyd-MkO1PFQ{PTd:L3G+
HK-2	MXnBdI9xfG:\|aYOgRZN{[Xl?	M1SyVlIxyqEQvF2=	MmnCNlQhcA>?		MUDpcohq[mm2czDFVmsh[W6mIICzPG1CWEt?	NF\1fHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0N\|E2OSd-MkO1OFMyPTF:L3G+
H9c2	MVfGeY5kfGmxbjDBd5NigQ>?	MV6xxsDPxE1?	MnPuNUBp		Mn7ldoVlfWOnczDUUmYu\|rFvaX7keYNm\CCPTWCtPUBuWk6DIHzleoVteyCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm=	NH20OVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1N\|Y6QSd-MkOzOVM3QTl:L3G+
H9c2	M1zhUmZ2dmO2aX;uJGF{e2G7	M2LoRlHDqM7:TR?=	NFvsRnQyKGh?		M3vnOpJm\HWlZYOgWG5HNc7zLXXubIFv[2WmIFHQMVEheHKxbX;0[ZIh[WO2aY\peJk>	NH:1d5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1N\|Y6QSd-MkOzOVM3QTl:L3G+
H1650	M3nudWZ2dmO2aX;uJGF{e2G7	NXHXbm1sOTEEoN88UeKh	NIPZZWsyKGh?	MV3EUXNQ	NUXiZVY2\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?=	NYTiVG1ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1703	MX7GeY5kfGmxbjDBd5NigQ>?	M2DqdFExyqEQvF5CpC=>	NUi2PFl6OSCq	Ml;hSG1UVw>?	NFnRN\|dl\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:\|ZXVCpINmdGy\|	NUSycItGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1650	M{O3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml24NVDDqM7:TdMg	M{HZ[\|EhcA>?	MnzYSG1UVw>?	NETD[opmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[3m2b4TvfIlkcXS7	NXrRdXNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1703	NWjYOldtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInTN5cyOMLizszNxsA>	M4X1WlEhcA>?	Mon3SG1UVw>?	MWrlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6	NYrMU5ZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
medulloblastoma cells	NEi3b5FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				M370SmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibXXkeYxtd2KuYYP0c41iKGOnbHzzJIhiemKxcnnu[{Bp\XSncn;6fYdwfXNicITjbFEh\2WwZTDifUBOXFRiYYPzZZktKEWFNUCgQUA{NjByNjFOwG0v	M3\oelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG3OlMyLz5zN{SxO\|Y{OTxxYU6=
neural precursor cells	NYmw[JNFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				MnHqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCwZYXyZYwheHKnY4Xyd49zKGOnbHzzJIJ6KE2WVDDhd5NigSxiRVO1NEA:KDhwME[zJO69VS5?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-
RAW264.7	MWHBcpRqcW6obHHtcYF1d3K7IHHzd4F6		M33EOVExKG2rboO=		NGLNNHRCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiCrbnP1ZoF1\WRiZn;yJFExKG2rboOgdJJqd3JidH:gUHBUNWOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAyQCCqcoOgZpkhT3KrZYPzJI1mfGixZDygTWM2OCB;IEG2JO69VS5?	NV[xZmlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N\|E4QThpPkKyPFMyPzl6PD;hQi=>
BL21(DE3)	NVfXUWllTnWwY4Tpc44h[XO\|YYm=		M2m3WFYxKG2rboO=		NFLoc2RKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhSlKGNDDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzKFTFN{kh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJIhqe3SxbnWgTFQheGWydHnk[UBieyC\|dXLzeJJifGViYX\0[ZIhPjBibXnud{BjgSCDbIDoZXNkemWnbjDhd5NigSxiSVO1NEA:KDNwNDFOwG0v	M2PFZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUm1O\|I{Lz5{OEG5OVczOzxxYU6=
RAW264.7	MmjkSpVv[3Srb36gZZN{[Xl?				Mn\SVJJwfGWldHnvckBi\2GrboP0JGJi[2mubIXzJIFvfGi{YXPpd{Bxem:2ZXP0bZZmKGGwdHnn[Y4h[W6mIHzleIhidCC2b4jpck1lcXCqdHjldoliKHSxeHnuJINpcW2ncnnjJJBzd3SnaX6gcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6KGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5	NVzwUoE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PFU2ODRpPkG3OFg2PTB2PD;hQi=>
A673	MXfxTHRUKGG\|c3H5				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MlrMdWhVWyCjc4PhfS=>				MkPVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	MkfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M{PSSZFJXFNiYYPzZZk>				M1XvNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	M13TOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NG\SRmlyUFSVIHHzd4F6				NWT1TWFJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NFS2flc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	M1;aOpFJXFNiYYPzZZk>				NXjGR4R5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	MknqdWhVWyCjc4PhfS=>				MoLCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUGFPNTViY3XscJM>	NYX0dWlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NUD2NWtveUiWUzDhd5NigQ>?				NFOxbGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	NIjOSXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MWTxTHRUKGG\|c3H5				NXHpXW9keUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NVrZTpNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	Moj6dWhVWyCjc4PhfS=>				NXL6NHcxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	MVrxTHRUKGG\|c3H5				NXvRT2RleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	Mm\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NFPYOIlyUFSVIHHzd4F6				NWm5[lJmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	M{PaRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	Mo[xdWhVWyCjc4PhfS=>				NFnkPG9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	MlXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	MYfxTHRUKGG\|c3H5				NIXTVJFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{	MlrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NVGyd4ZQeUiWUzDhd5NigQ>?				M1;FV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtew>?	M4jOb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NUL0dINDeUiWUzDhd5NigQ>?				MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	MluzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	Ml\adWhVWyCjc4PhfS=>				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	M2\k[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MmOydWhVWyCjc4PhfS=>				NYPi[5BXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NF63SXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NGm0ZmdyUFSVIHHzd4F6				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	MljTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	M3[3cZFJXFNiYYPzZZk>				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{	NX;VOGN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	MorRdWhVWyCjc4PhfS=>				NF7UZ3dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NXzXbW04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NInwSlZyUFSVIHHzd4F6				M3fkRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	M4\VeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	- Collapse Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%H2O For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 (RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib dimesylate

Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X, GW856553, GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)